These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 22252622)

  • 21. Multikinase inhibitors for treating high-risk myelodysplastic syndromes: can this be brought into clinical practice?
    Duong VH; Padron E; List AF; Komrokji RS
    Expert Rev Hematol; 2013 Oct; 6(5):485-7. PubMed ID: 24083503
    [No Abstract]   [Full Text] [Related]  

  • 22. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
    J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imatinib and regression of type 2 diabetes.
    Veneri D; Franchini M; Bonora E
    N Engl J Med; 2005 Mar; 352(10):1049-50. PubMed ID: 15758023
    [No Abstract]   [Full Text] [Related]  

  • 24. Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.
    Potenza L; Volzone F; Riva G; Soverini S; Martinelli S; Iacobucci I; Gnani A; Barozzi P; Forghieri F; Morselli M; Zanetti E; Maccaferri M; Baccarani M; Martinelli G; Torelli G; Luppi M
    Br J Haematol; 2009 Jul; 146(2):227-30. PubMed ID: 19545285
    [No Abstract]   [Full Text] [Related]  

  • 25. [Tyrosine kinase inhibitors in tumor therapy--part 1. Molecular and genetic fundamentals].
    Grimm CF; Blum HE; Geissler M
    Dtsch Med Wochenschr; 2005 May; 130(21):1318-22. PubMed ID: 15902620
    [No Abstract]   [Full Text] [Related]  

  • 26. [The tyrosine kinase antagonist imatinib mesylate].
    Heinzl S
    Med Monatsschr Pharm; 2002 Jan; 25(1):4-7. PubMed ID: 11826665
    [No Abstract]   [Full Text] [Related]  

  • 27. Renal failure associated with tyrosine kinase inhibitors--case report and review of the literature.
    Gafter-Gvili A; Ram R; Gafter U; Shpilberg O; Raanani P
    Leuk Res; 2010 Jan; 34(1):123-7. PubMed ID: 19640584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economics and the new generation of targeted therapies for non-small cell lung cancer.
    Ramsey SD
    J Natl Cancer Inst; 2010 Mar; 102(5):287-8. PubMed ID: 20160167
    [No Abstract]   [Full Text] [Related]  

  • 30. Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases.
    Chase A; Cross NC
    Clin Sci (Lond); 2006 Oct; 111(4):233-49. PubMed ID: 16961463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
    Bradbury PA; Tu D; Seymour L; Isogai PK; Zhu L; Ng R; Mittmann N; Tsao MS; Evans WK; Shepherd FA; Leighl NB;
    J Natl Cancer Inst; 2010 Mar; 102(5):298-306. PubMed ID: 20160168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of acute leukemias and chronic myeloid leukemias].
    Devergie A
    Soins; 2008 Mar; (723):44-5. PubMed ID: 18380312
    [No Abstract]   [Full Text] [Related]  

  • 33. Reduction of BCR-ABL1 mutant clones after discontinuation of TKI therapy.
    Beel K; Janssens A; Verhoef G; Vandenberghe P
    Leuk Res; 2009 Dec; 33(12):1703-5. PubMed ID: 19457553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pulmonary toxicities of tyrosine kinase inhibitors.
    Peerzada MM; Spiro TP; Daw HA
    Clin Adv Hematol Oncol; 2011 Nov; 9(11):824-36. PubMed ID: 22252615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Patient-specific cost calculation--a good way to evaluate new therapeutic methods].
    Westin J
    Lakartidningen; 2003 Oct; 100(42):3304-6. PubMed ID: 14619039
    [No Abstract]   [Full Text] [Related]  

  • 36. [Imatinib--a new perspective in the treatment of tumors].
    Klener P; Klamová H
    Cas Lek Cesk; 2004; 143(9):579-80, 582-3. PubMed ID: 15532894
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New approaches to thyroid cancer.
    Cohen EE
    Clin Adv Hematol Oncol; 2012 Apr; 10(4):255-6. PubMed ID: 22706487
    [No Abstract]   [Full Text] [Related]  

  • 38. [Chronic myeloid leukemia: "archetype" of the impact of targeted therapies].
    Nasr R; Bazarbachi A
    Pathol Biol (Paris); 2012 Aug; 60(4):239-45. PubMed ID: 22743097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of gastrointestinal stromal tumors--initial experience.
    Lupaşcu C; Andronic D; Moldovanu R; Târcoveanu E; Georgescu S; Ferariu D
    Chirurgia (Bucur); 2010; 105(5):657-62. PubMed ID: 21141090
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peripheral neuropathy as an adverse effect of imatinib therapy.
    Chakupurakal G; Etti RJ; Murray JA
    J Clin Pathol; 2011 May; 64(5):456. PubMed ID: 21278395
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.